Conduit Pharmaceuticals to explore cryptocurrency reserve strategy

Conduit Pharmaceuticals (CDT) has engaged a third-party consultant to evaluate and advise on the potential adoption of a part cryptocurrency treasury reserve strategy. This initiative is designed to better inform the company on current cryptocurrency market dynamics and support a broader capital diversification framework aligned with innovation and digital asset trends. The company believes that a partial cryptocurrency reserve could offer long-term optionality and diversified capital utility, enabling a portion of its balance sheet to participate in what Conduit views as an increasingly mature and institutionally adopted asset class. The company remains committed to the progression of its pharmaceutical assets, including its core focus on leveraging artificial intelligence and solid-form technologies to generate intellectual property protection, and licensing activities across autoimmune and rare disease areas.